• +1-646-491-9876
    • +91-20-67278686

    Search

    T Cell Specific Surface Glycoprotein CD28-Pipeline Review H1 2017

    T Cell Specific Surface Glycoprotein CD28-Pipeline Review H1 2017

    • Report Code ID: RW0001834449
    • Category Pharmaceuticals
    • No. of Pages 49
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Pipeline Review, H1 2017

    Summary

    T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - CD28 is a proteins expressed on T cells. It co-stimulates signals required for T cell activation and survival. It enhances the production of IL4 and IL10 in T-cells in conjunction with TCR/CD3 ligation and CD40L co-stimulation.

    T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 2 and 2 respectively. Report covers products from therapy areas Immunology, Oncology, Central Nervous System, Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders, Musculoskeletal Disorders, Ophthalmology and Toxicology which include indications Graft Versus Host Disease (GVHD) , Rheumatoid Arthritis, Systemic Lupus Erythematosus, Acute Renal Failure (ARF) (Acute Kidney Injury) , Arthritis, B-Cell Chronic Lymphocytic Leukemia, Gastrointestinal Radiation Toxicity, Hypersensitivity, Kidney Transplant Rejection, Multiple Sclerosis, Pancreatitis, Plaque Psoriasis (Psoriasis Vulgaris) , Psoriasis, Sicca Syndrome (Sjogren) , Skin And Soft Tissue Infections, Solid Tumor, Type 1 Diabetes (Juvenile Diabetes) and Uveitis.

    The latest report T Cell Specific Surface Glycoprotein CD28 - Pipeline Review, H1 2017, outlays comprehensive information on the T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)
    - The report reviews T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics and enlists all their major and minor projects
    - The report assesses T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Overview
    T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Companies Involved in Therapeutics Development
    Atox Bio Ltd
    Bristol-Myers Squibb Company
    Five Prime Therapeutics Inc
    OSE Immunotherapeutics
    TheraMAB LLC
    T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Drug Profiles
    ALPN-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FPT-155 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FR-104 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lulizumab pegol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Agonize CD278 and CD28 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein to Agonize CD278 and CD28 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    reltecimod sodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TAB-08 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Dormant Products
    T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Discontinued Products
    T Cell Specific Surface Glycoprotein CD28 (TP44 or CD28) - Product Development Milestones
    Featured News & Press Releases
    May 23, 2017: Atox Bios Reltecimod Passes Futility Analysis in Phase 3 ACCUTE Study; Trial Continues as Planned
    Nov 17, 2016: OSE Immunotherapeutics announces the online publication of positive Phase 1 clinical results with FR104 in the Journal of Immunology
    Nov 03, 2016: Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study Of AB103 In Necrotizing Soft Tissue Infections
    Jun 15, 2016: Atox Bio Awarded Next Milestone-based Option by BARDA to Support Development of AB103 for Necrotizing Soft Tissue Infections
    Dec 07, 2015: Atox Bio Enrolls First Patient in Phase 3 Study of Potential Treatment for Necrotizing Soft Tissue Infection (Flesh Eating Bacteria)
    Jul 09, 2015: Effimune launches Phase I clinical trial on immune system regulation control
    Apr 15, 2015: Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104
    Feb 12, 2015: Two major scientific articles validate Effimune's drug candidate and reinforce the proof of concept of the technology aimed at regulating the immune system
    Dec 25, 2014: TheraMAB presents new clinical data on theralizumab (TAB08) at Nature Biotechnology
    Sep 29, 2014: Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority
    Aug 05, 2014: AB103 Granted Orphan Medicinal Product Designation in the European Union for the Treatment of Necrotizing Soft Tissue Infections
    Jan 14, 2014: TheraMAB announces initiation of Phase II clinical trial of mAb TABO8 for the treatment of Rheumatoid Arthritis
    Apr 09, 2013: Atox Bio Publishes Data Demonstrating Broad Therapeutic Effect Of Flagship Product In Treating Flesh Eating Bacteria
    Nov 20, 2012: Atox Bio Announces Positive Top-line Results In AB103 Necrotizing Soft Tissue Infections Phase IIa Trial
    Sep 10, 2012: Atox Bio's AB103 Receives FDA Fast Track Designation For Treatment Of Necrotizing Soft Tissue Infections
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Atox Bio Ltd, H1 2017
    Pipeline by Bristol-Myers Squibb Company, H1 2017
    Pipeline by Five Prime Therapeutics Inc, H1 2017
    Pipeline by OSE Immunotherapeutics, H1 2017
    Pipeline by TheraMAB LLC, H1 2017
    Dormant Projects, H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Atox Bio Ltd
    Bristol-Myers Squibb Company
    Five Prime Therapeutics Inc
    OSE Immunotherapeutics
    TheraMAB LLC

    Request for Sample

    Report Url http://www.reportsweb.com//t-cell-specific-surface-glycoprotein-cd28-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//t-cell-specific-surface-glycoprotein-cd28-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//t-cell-specific-surface-glycoprotein-cd28-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments